April 12, 2017
argenx enters Phase II trial of CTCL drug
argenx has initiated a Phase II trial of ARGX-110 as a monotherapy in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).
Pharmaceuticals, Biotechnology and Life Sciences
Tag: cutaneous T-cell lymphoma (CTCL)